At the recent ASCO 2013 meeting in Chicago, I had the great pleasure to interview Susan M. O’Brien, MD who is the Ashbel Smith Professor in the Department of Leukemia at the University of Texas, MD Anderson Cancer Center in Houston, and someone who is making a difference to the lives of CLL patients.
I first met Dr O’Brien over ten years ago when I was at Novartis Oncology in new products working on bringing to market what was then known as STI571, and subsequently became Gleevec.
In the same way that tyrosine kinase inhibitors forever changed CML, the treatment of Chronic Lymphocytic Leukemia (CLL) is set to undergo a major transformation over the next few years.
I hope you will enjoy this video interview in which Dr O’Brien discusses some of the CLL data presented at ASCO ’13 and shares her perspective on several of the new targeted agents in development. It’s an exciting time in CLL!